The packet lists no known genes and no entries in the inheritance field, so the genes involved are not characterized in the structured portion of the packet. The condition name refers to qualitative or quantitative defects of dysferlin. The GeneReviews genetic counseling section states that dysferlinopathy is inherited in an autosomal recessive manner and that carriers are asymptomatic and not at risk of developing the disorder. GeneReviews also reports intrafamilial variability, with Miyoshi muscular dystrophy, limb-girdle muscular dystrophy type 2B, and distal myopathy with anterior tibial onset reported in the same family. Its genotype-phenotype section reports that two specific pathogenic variants were associated with MMD, one of them with a milder form of MMD and LGMD2B.

GeneReviews states that no consensus clinical diagnostic criteria for dysferlinopathy have been published. It describes suspicion based on the two major phenotypes and consideration based on the two minor phenotypes. Findings listed for MMD include onset in mid- to late childhood or early adulthood (mean 19.0 years), early and predominant distal weakness particularly of the calf muscles, slow progression, serum CK often 10 to 100 times normal, and a primarily myogenic pattern on EMG. Findings listed for LGMD2B include early pelvic and shoulder girdle weakness and atrophy, onset in the late teens or later, slow progression, massive CK elevation, and subclinical distal involvement. A family history consistent with autosomal recessive inheritance is described as informative, while the absence of a known family history does not preclude the diagnosis.

According to GeneReviews, the diagnosis is established in a proband with suggestive findings and biallelic pathogenic or likely pathogenic variants identified by molecular genetic testing. Identification of biallelic variants of uncertain significance is described as neither establishing nor ruling out the diagnosis. Testing approaches named include single-gene testing, multigene panels, exome sequencing, and genome sequencing.

The GeneReviews differential diagnosis discusses other autosomal recessive limb-girdle muscular dystrophies, the dystrophinopathies, and several distal myopathies. No newborn screening information is present in the packet.

The packet lists no FDA-approved treatments, no orphan drug records, and no foundational therapy entries. GeneReviews states that no clinical practice guidelines for dysferlinopathy have been published and that there is no approved therapy; treatment is described as symptomatic only.

GeneReviews describes initial evaluations covering musculoskeletal function, respiratory function with pulmonary function tests, cardiac status with a baseline echocardiogram, genetic counseling, and family support resources. Its treatment table lists physical therapy and rehabilitation medicine with assistive devices, orthopedic surgery for complications such as foot deformity and scoliosis, occupational therapy, respiratory management by a treating pulmonologist (described as a concern mostly in nonambulatory persons), and social and emotional support. GeneReviews describes surveillance by a multidisciplinary team at least annually.

The packet does not certify a formal natural history entry, so this section follows the GeneReviews clinical description. Both major phenotypes are described as slowly progressive. The GeneReviews comparison table reports, as averages from cited studies, that a cane was required at about 35.5 years in MMD and 39.3 years in LGMD2B, and that individuals became wheelchair-bound at about 42.8 years in MMD and 45.1 years in LGMD2B, about 22.8 and 21.4 years after onset. These are group averages reported in the chapter, and the table lists these milestones as asymptomatic or unknown for the minor phenotypes. Respiratory involvement is described as mostly a concern in nonambulatory persons, and GeneReviews describes asymptomatic hyperCKemia as usually a presymptomatic stage in individuals who eventually develop weakness.

The packet certifies that at least one active ClinicalTrials.gov record is associated with the condition, but no trial details are included, and the trial interventions are classified only as other interventions. The packet's publication summary indicates that gene therapy and biomarker publications are present. The GeneReviews section on therapies under investigation describes preclinical work: a comparison of prednisolone with vamorolone in which vamorolone stabilized dysferlin-deficient muscle cell membranes and improved repair in dysferlin-deficient mouse myofibers; antisense oligonucleotide exon skipping that corrected aberrant pseudoexon splicing in vitro and restored dysferlin protein expression; and work showing that an AMP-activated protein kinase activator rescued membrane-repair impairment in human myotubes with reduced dysferlin and in dysferlin-null mouse fibers. GeneReviews presents these as investigational, and the packet does not certify any as an available therapy.